History

The Story Over Time

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The HUL story has narrowed. Five years ago Sanjiv Mehta sold a "Compass" of five Growth Fundamentals threaded through a triumphalist post-COVID share-gain narrative; today Priya Nair sells four BU pillars, a "SASSY" framework, and the simpler argument that volume growth has finally turned. In between sits a credibility cost: two consecutive years of 2% UVG against a self-set "double-digit EPS growth" ambition, an EBITDA-margin band that was quietly walked down from 23-24% to 22-23%, and five straight quarters of "demand recovery is around the corner" before recovery actually arrived in Q3 FY26. The current story is cleaner — premiumisation, channels of the future, ice-cream-out-Minimalist-in — but it is also a smaller story than the one Mehta used to tell, and credibility has improved only because the bar was reset, not because past promises were honoured.

1 · The Narrative Arc

The revenue picture is deceptively smooth. After GSK Consumer Healthcare merged in FY21 and inflation lifted FY22-FY23 prices, top line stalled: $7.37B → $7.42B → $7.39B → $6.87B is a flat USD trajectory across four years (with the FY26 step-down reflecting INR depreciation rather than business decline) against an FMCG industry that price-led grew at near-double digits in some windows. The two metrics management actually reports in the call — UVG and underlying sales growth — tell the truer story: a multi-quarter consumption trough that took five quarters of "modest improvement" promises before turning.

2 · What Management Emphasised — and Then Stopped Emphasising

Three patterns are doing the work in this chart:

Frameworks have a half-life of one CEO. Compass + the Five Growth Fundamentals were the official strategy in every annual report from FY21 to FY23, then died on Mehta's last day. ASPIRE replaced them in FY24-FY25; under Nair, ASPIRE is still cited but no longer leads — the four BU pillars and SASSY do. "Core / Future Core / Market Makers" — debuted at the November 2024 Capital Markets Day and central to four straight transcripts — is essentially gone six months into Nair's tenure.

"Reimagine HUL" was real capability, then a faded brand. Shikhar (1.4mn outlets), nano-factories, three "Lighthouse" plants and the Supply Chain Nerve Center are still there; the slogan is gone. Reimagine HUL is the cleanest example of an initiative that delivered, embedded, and was retired without ceremony.

Stratos illustrates the opposite. Heavily flagged Q2-Q3 FY25 — "twenty patents, five years to develop" — and absent from FY26 calls, replaced by Pears/Dove premium-soap framing. Skin Cleansing did recover by Q4 FY26 ("highest growth in 12 quarters"), but the win was reframed from mass-Lifebuoy-relaunch to premium-Pears-and-Dove. Stratos is the counter-example: heavy storytelling, quiet exit.

3 · Risk Evolution

The risk register has migrated decisively from input-side (palm oil, crude, packaging, COVID) to demand-side and channel-side (urban slowdown, q-commerce, GenZ disruptors). COVID was effectively erased after FY22. Quick commerce went from a footnote in FY21 to a structural channel in FY25 with its own dedicated org by Q3 FY26 (a 3% revenue channel "doubling every quarter"). Macro/geopolitical risk was promoted onto the FY24 materiality matrix. The novel FY26 risk — the September-2025 GST rate cut on FMCG goods — was disclosed in Q2 FY26 as "transitory destocking impacting ~40% of the portfolio," cost the quarter ~3% of growth, and was explicitly used to justify the year's narrowest USG print (2%).

Two risks the company has historically underdiscussed: (1) the 5-year EBITDA-margin contraction from 25.0% to 23.5%, never explicitly addressed as a structural shift; (2) the GSK Consumer Healthcare/Horlicks underperformance — the largest FMCG M&A in India's history (FY21) is now described in FY25 as showing "muted growth due to consumption headwinds," six years after the deal closed.

4 · How They Handled Bad News

The dominant pattern is frame-as-transitory-and-defer, used three times across this two-year window — twice unsuccessfully.

Two of the six framings aged badly. The "transitory small pack" claim (Q3 FY25) was repeated for at least three quarters before being absorbed into the new "Power-Spenders / Premiumisers / Democratisers" segmentation under Nair — i.e. the down-trading wasn't reversed, it was reclassified as a structural cohort. And the Q4 FY25 denial that the margin cut had anything to do with "Home Care pricing" was directly contradicted by Reuters reporting in February 2026 that HUL had "cut prices in tea and home care to stave off competition" — a textbook case of the company saying one thing on a call and the action telling a different story a year later.

Two were honest and held up. The Q4 FY25 "play to win" speech, which accompanied the 100 bps margin guidance cut, made the trade-off explicit (margin for share). The Q2 FY26 GST-transition explanation was specific, falsifiable, and validated the next quarter when growth re-accelerated.

5 · Guidance Track Record

The band was lowered once (Q4 FY25, –100 bps) and then reset upward (Q3 FY26, +50 bps low end / +50 bps high end) once the ice-cream demerger removed the dilutive sub-segment from continuing operations — a roughly 50–60 bps optical lift, by management's own admission. So the FY26-end "band" of 22.5-23.5% is structurally not the same animal as the FY24 "23-24%": the comparable like-for-like FY27 floor is closer to 22%. This nuance was disclosed honestly in Q3-Q4 FY26 calls but is not always carried through in commentary.

Direction: Improving from 5 (Jul 2025) → 6 (May 2026) under Nair.

Credibility verdict: 6 / 10, improving. What pulls the score down: (a) the FY24 "double-digit EPS growth" promise was missed in FY25 and not directly addressed; (b) the Q3 FY25 "small pack transitory" framing was repeated for too long and effectively walked back via cohort reclassification; (c) the Q4 FY25 denial that the margin cut had anything to do with home-care pricing was contradicted by external reporting a year later; (d) the original 23-24% margin band was abandoned and only re-floored after a structural optical lift. What lifts the score: ice cream demerger executed cleanly (Sep 2024 announce → Dec 2025 complete), Minimalist closed early, Q4 FY26 broad-based 7% USG validated the H2-better-than-H1 promise, and Nair's first 90 days delivered on the unified India org and a sharper segmentation framework rather than vague aspirations. The Mehta-era credibility (≈7) was earned through pandemic execution; the Jawa-era credibility (≈4-5) was eroded by the strategy churn and the missed double-digit EPS promise; the Nair-era trajectory (≈6 and rising) rests on one good half-year — needs another year of delivery to fully recover.

6 · What the Story Is Now

The current Nair-era story has three parts.

Part 1 — Volume growth is back. Q4 FY26 USG of 7% with UVG of 6% is the highest in 12 quarters and is broad-based across all four segments (Home Care, B&W, Personal Care, Foods). The "modest improvement" promise that was repeated for five quarters has, finally, been delivered. The H2 FY26 acceleration is real, validated by the GST cut tailwind playing out as management said it would, and corroborated by independent retail audit data.

Part 2 — Premiumisation is now the central thesis, not a sub-bullet. The $212M two-year capex commitment (Apr 2026) is explicitly earmarked for Beauty & Wellbeing and home-care liquids. Beauty & Wellbeing is the highest-margin segment (~32% EBIT vs 17% Personal Care). Minimalist (closed Apr 2025 for $317M) plus the OZiva 49% top-up ($92M, Q3 FY26) plus Liquid IV plus Nexxus give HUL a credible premium-beauty stack it didn't have under Mehta. The flip side: mass-market Personal Care (Lifebuoy, Glow & Lovely, Clinic Plus) is no longer where the wins are coming from, and Foods/Lifestyle Nutrition (Horlicks, Boost) is still flagged as muted six years after the GSK CH deal.

Part 3 — The portfolio is being sharpened. Ice cream out (KWIL listed Feb 2026), Pureit out (Nov 2024, ~$70M), Wellbeing Nutrition out (Dec 2025 to USV for $34M), Minimalist + OZiva consolidation in. The "Reshape Portfolio" pillar from the FY24 strategy is the one that has actually been executed.

What still looks stretched:

• Foods. Lifestyle Nutrition has been a problem child for the entire post-GSK era; Knorr/Kissan/Hellmann's are good businesses but small. The "Horlicks Taller, Stronger, Sharper" repositioning has not produced headline growth.
• EBITDA margin recovery. The 22.5-23.5% band requires an underlying ~22% to 22.5% on a like-for-like basis post ice-cream optical lift — that is a floor, not a path back to the historical 25%.
• GenZ / quick-commerce competition. HUL has built the channel infrastructure, but D2C disruptors (Mamaearth/Honasa, Plum, Mokobara, dozens more) continue to take share in premium beauty — the very space the Minimalist deal was supposed to defend.
• The valuation. At ~49x trailing P/E and 22.3% ROE, the market is pricing in a successful Nair turnaround that is one good half-year old.

What the reader should believe vs discount. Believe: ice-cream demerger optics, Minimalist integration progress, q-commerce 3% and growing, Power-Spenders cohort framework as a useful internal tool, broad-based H2 FY26 acceleration. Discount: any forward "double-digit" growth language until two consecutive years of high-single-digit USG arrive; any margin guidance that doesn't explicitly net out the ice-cream demerger lift; the company's own framing that mass-market Personal Care has "recovered" — the recovery is premium-led, mass remains structurally challenged.

The story has grown smaller, simpler, and (as of Q4 FY26) more truthful. That is genuine progress. Whether it's enough to support a 49× multiple still rests on the next two to four quarters of underlying delivery.